阿普米司特对皮损面积有限、特殊部位受累且生活质量受损的斑块状银屑病患者的疗效与安全性:EMBRACE随机试验结果
EMBRACE是一项4期随机安慰剂对照多国研究,纳入277例局部治疗未控制、至少1个特殊部位受累、PASI≥3至≤10且DLQI>10的斑块状银屑病患者。第16周时阿普米司特组DLQI应答(≥4分下降)比例显著高于安慰剂组(73.3% vs 41.3%,p<0.0001),瘙痒和皮肤不适/疼痛也显著改善,未发现新的安全性信号。
要点
- 阿普米司特30 mg每日两次显著改善特殊部位斑块状银屑病患者皮肤相关生活质量。
- 第16周DLQI应答率阿普米司特组73.3%,安慰剂组41.3%(p<0.0001)。
- 瘙痒和皮肤不适/疼痛评分改善及患者获益指数≥1达成率均显著优于安慰剂。
核心结论
- 阿普米司特显著改善皮损面积有限、特殊部位受累且生活质量高度受损的斑块状银屑病患者的皮肤相关生活质量,安全性特征与既往阿普米司特研究一致。
研究设计与样本
- EMBRACE(NCT03774875)为4期随机安慰剂对照多国研究,共随机277例患者(阿普米司特组185例,安慰剂组92例),221例完成第16周(阿普米司特组152例,安慰剂组69例)。
- 纳入标准为局部治疗未控制的斑块状银屑病、对常规一线系统治疗缺乏应答/禁忌/不耐受、至少1个特殊部位受累(包括可见部位、头皮、甲、生殖器部位或掌跖部位)、PASI≥3至≤10且DLQI>10。
主要发现
- 第16周DLQI应答(≥4分下降)率阿普米司特组为73.3%,安慰剂组为41.3%(p<0.0001)。
- 第16周阿普米司特组较安慰剂组在受累体表面积(BSA)和PASI方面观察到显著更大的改善。
- 第16周瘙痒数字评定量表变化阿普米司特组为-2.5,安慰剂组为-0.9(p<0.0001);皮肤不适/疼痛视觉模拟量表变化阿普米司特组为-21.5,安慰剂组为-5.4(p=0.0003)。
- 第16周患者获益指数≥1达成率阿普米司特组为77%,安慰剂组为40%(p<0.0001)。
- 未观察到新的安全性信号。
关键数值与推荐
- 主要终点为第16周DLQI应答(≥4分下降)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION/BACKGROUND: Manifestations of psoriasis in special areas are difficult to treat and are associated with a high disease burden and significant quality of life (QoL) impairment. Topical therapies may be inadequate for these patients, necessitating systemic treatment. OBJECTIVE: The objective of EMBRACE was to evaluate the impact on QoL, efficacy and safety of apremilast 30 mg BID in patients with limited skin involvement with plaque psoriasis manifestations in special areas and impaired QoL. METHODS: EMBRACE (NCT03774875) was a phase 4, randomized, placebo-controlled, multinational study. Patients had plaque psoriasis not controlled by topical therapy; lack of response, contraindication or intolerance to conventional first-line systemic therapy; psoriasis in ≥1 special area (including visible locations, scalp, nails, genital areas or palmoplantar areas); Psoriasis Area and Severity Index (PASI) ≥3 to ≤10; and Dermatology Life Quality Index (DLQI) >10. The primary endpoint was DLQI response (≥4-point reduction) at Week 16. RESULTS: Of 277 randomized patients (apremilast: n = 185; placebo: n = 92), 221 completed Week 16 (apremilast: n = 152; placebo: n = 69). The primary endpoint (≥4-point reduction in DLQI at Week 16) was met by significantly more patients receiving apremilast (73.3%) versus placebo (41.3%; p < 0.0001). Significantly greater improvement in affected body surface area (BSA) and PASI was observed with apremilast versus placebo at Week 16. There were also significantly greater improvements with apremilast versus placebo in itch numeric rating scale (-2.5 vs. -0.9, p < 0.0001) and skin discomfort/pain visual analog scale (-21.5 vs. -5.4, p = 0.0003) and greater achievement of Patient Benefit Index ≥1 (77% vs. 40%, p < 0.0001) at Week 16. No new safety signals were observed. CONCLUSIONS: Apremilast significantly improved skin-related QoL in patients with limited skin involvement with plaque psoriasis in special areas and highly impaired QoL. The safety profile was consistent with prior apremilast studies.
引用
- Mrowietz U, Barker J, Conrad C, et al. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial. J Eur Acad Dermatol Venereol. 2022. PMID: 36300769. doi:10.1111/jdv.18689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。